Get startedLog in
    Picture of Theratechnologies logo

    TH — Theratechnologies News Story

    0.000.00%
    ca flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapTurnaround
    All News

    Brief: Theratechnologies Provides Update On Dose Escalation Portion Of Fast Track Designated TH1902 First-In-Human Study In Advanced Resistant Malignancies

    Picture of Theratechnologies logoTheratechnologies
    14/07/2022 12:05
    July 14 (Reuters) - Theratechnologies Inc  TH.TO :
    * THERATECHNOLOGIES PROVIDES UPDATE ON THE DOSE ESCALATION
PORTION
OF FAST TRACK DESIGNATED TH1902 FIRST-IN-HUMAN STUDY IN ADVANCED
RESISTANT MALIGNANCIES
    * THERATECHNOLOGIES INC - CONFIRMED SAFETY PROFILE AT 300
MG/M(2)
OR 1.5 TIMES THERAPEUTIC DOSE OF DOCETAXEL ALONE
    * THERATECHNOLOGIES INC - CONFIRMED LOW LEVELS OF FREE
DOCETAXEL
CONSISTENT WITH OBSERVATIONS IN ANIMAL STUDIES
    * THERATECHNOLOGIES INC - EARLY SIGNS OF EFFICACY OBSERVED
IN DOSE
ESCALATION PORTION OF STUDY
    * THERATECHNOLOGIES INC - ENROLLMENT OF CLINICAL TRIAL SITES
CONTINUE WITH 6 MAJOR CANCER CENTERS ACTIVATED

Source text for Eikon:  ID:nGNXb69MwM 
Further company coverage:  TH.TO 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Theratechnologies

    See all news